Retro-2 Enhances Tumor-Cell MHC-I Antigen Presentation and CD8+ T Cell-Dependent Antitumor Immunity
International Journal of Molecular Sciences · 20.11.2026 · 27 (22) · 10449
DOI: 10.3390/ijms272210449 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 20.11.2026. Verfasst von Zhuo-Shuo Xu und 5 weiteren Autor:innen. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: State Key R&D Program of China, Fundamental Research Funds for the Central Universities, Natural Science Foundation Exploration Program (Morning Light Program) of Wuhan City.
Abstract (Originalsprache)
Defective major histocompatibility complex class I (MHC-I) antigen presentation enables tumor immune evasion and limits programmed cell death protein 1 (PD-1) blockade efficacy. We tested whether pharmacological enhancement of tumor-cell MHC-I presentation could restore immunogenicity and sensitize tumors to checkpoint therapy. Retro-2, a cyclic inhibitor of retrograde toxin trafficking, increased MHC-I transcripts, surface MHC-I/HLA-ABC, and peptide–MHC-I presentation in murine B16-F10 melanoma and Panc02 pancreatic cancer cells and in human A375 melanoma and BxPC-3 pancreatic cancer cells. These changes enhanced antigen-specific CD8+ T cell killing and IFN-γ/TNF-α release, and increased human tumor-cell susceptibility to tumor-lysate-primed CD8+ T cells. In syngeneic mouse models of B16-F10 melanoma and Panc02 pancreatic cancer, Retro-2 delayed tumor growth, reduced tumor burden, and prolonged survival, accompanied by increased intratumoral CD8+ T cell abundance, proliferation, effector function, and progenitor-exhausted cells. CD8+ T cell depletion largely abolished Retro-2 activity. Combining Retro-2 with PD-1 blockade produced greater tumor control than either monotherapy in both models. Retro-2 was well tolerated, with no detectable changes in body weight, hematological indices, or major-organ histology. These findings identify Retro-2 as a pharmacological enhancer of tumor MHC-I presentation that promotes CD8+ T cell-dependent antitumor immunity and improves PD-1 blockade efficacy.
Förderung
- State Key R&D Program of China
- Fundamental Research Funds for the Central Universities
- Natural Science Foundation Exploration Program (Morning Light Program) of Wuhan City
Zitieren
APA
Xu, Z., Zhou, X., Zhang, Q., Jiang, K., Ruan, Z., & Hu, M. (2026). Retro-2 Enhances Tumor-Cell MHC-I Antigen Presentation and CD8+ T Cell-Dependent Antitumor Immunity. International Journal of Molecular Sciences, 27(22), 10449. https://doi.org/10.3390/ijms272210449
Vancouver
Xu Z, Zhou X, Zhang Q, Jiang K, Ruan Z, Hu M. Retro-2 Enhances Tumor-Cell MHC-I Antigen Presentation and CD8+ T Cell-Dependent Antitumor Immunity. International Journal of Molecular Sciences. 2026;27(22):10449. doi:10.3390/ijms272210449
BibTeX
@article{Xu2026,
author = {Xu, Zhuo-Shuo and Zhou, Xuan-Ang and Zhang, Qian and Jiang, Kai and Ruan, Zi-Lun and Hu, Ming-Ming},
title = {Retro-2 Enhances Tumor-Cell MHC-I Antigen Presentation and CD8+ T Cell-Dependent Antitumor Immunity},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {22},
pages = {10449},
doi = {10.3390/ijms272210449}
}
EUVIMED